NIH Awards $1.2M in Grants to Four Companies Developing RNAi, miRNA Cancer Drugs | GenomeWeb

Four companies developing RNAi/microRNA therapeutics received a combined $1.2 million in funding from the National Institutes of Health in September to develop their respective cancer drug candidates.

Among the firms are RXi Pharmaceuticals, Optimum Therapeutics, Ensysce Biosciences, and Mirna Therapeutics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Some 90 percent of respondents to a Nature survey say there is a research reproducibility crisis.

In Genome Research this week: transcriptomic analysis of the Venus flytrap, SMASH approach for CNV analysis, and more.

A Caltech professor wins the Millennium Technology Prize that lauds technological advances that improve human life.

San Diego's biotech scene has a dearth of executives who are women, Stat News reports.